{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T01:24:19Z","timestamp":1782177859463,"version":"3.54.5"},"reference-count":50,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,3]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>Although gout is one of the most common forms of inflammatory arthritis, it has been relatively neglected until recently. Despite progress in many areas of pathophysiology and genetics of gout and the development of new urate lowering therapies, there remain a number of unanswered clinical questions. With the resurgence of interest in gout it is important to recognize key aspects of gout management that remain challenging and require further research.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>The unanswered clinical issues outlined in this review are basic aspects of gout management that clinicians treating people with gout face on a daily basis and include when urate lowering therapy should be commenced, the most appropriate target serum urate, use of prophylaxis when starting urate lowering therapy and the most appropriate urate lowering therapy, particularly for those with chronic kidney disease.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>Some of the issues outlined in this article are the subject of ongoing clinical research and some, such as use of allopurinol in people with chronic kidney impairment, may be less relevant with the advent of potentially safer urate lowering therapies but until that time further understanding to aid clinical decision-making is required.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/bor.0000000000000367","type":"journal-article","created":{"date-parts":[[2016,12,6]],"date-time":"2016-12-06T17:09:20Z","timestamp":1481044160000},"page":"171-177","source":"Crossref","is-referenced-by-count":8,"title":["Major unanswered questions in the clinical gout field"],"prefix":"10.1097","volume":"29","author":[{"given":"Lisa K.","family":"Stamp","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230828","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1093\/rheumatology\/kem056a","article-title":"British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout","volume":"46","author":"Jordan","year":"2007","journal-title":"Rheumatology"},{"key":"R2-20230828","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1002\/acr.21773","article-title":"2012 American College of Rheumatology Guidelines for the Management of Gout. Part 2: Therapy and antiinflammatory prophylaxis of acute gouty arthritis","volume":"64","author":"Khanna","year":"2012","journal-title":"Arthritis Care Res"},{"key":"R3-20230828","article-title":"2016 updated EULAR evidence-based recommendations for the management of gout","author":"Richette","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"R4-20230828","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.3899\/jrheum.090370","article-title":"Outcome domains for studies of acute and chronic gout","volume":"36","author":"Schumacher","year":"2009","journal-title":"J Rheumatol"},{"key":"R5-20230828","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1002\/acr.21772","article-title":"2012 American College of Rheumatology guidelines for management of gout. Part 1: Systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia","volume":"64","author":"Khanna","year":"2012","journal-title":"Arthritis Care Res"},{"key":"R6-20230828","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.semarthrit.2010.09.003","article-title":"Serum urate as a soluble biomarker in chronic gout \u2013 evidence that serum urate fulfils the OMERACT validation criteria for soluble biomarkers","volume":"40","author":"Stamp","year":"2011","journal-title":"Semin Arthritis Rheum"},{"key":"R7-20230828","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1136\/ard.2006.060368","article-title":"Time required for disappearance of urate crystals from synovial fluid after successful hypouricaemic treatment relates to the duration of gout","volume":"66","author":"Pascual","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"R8-20230828","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1002\/art.10511","article-title":"Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout","volume":"47","author":"Perez-Ruiz","year":"2002","journal-title":"Arthritis Care Res"},{"key":"R9-20230828","doi-asserted-by":"crossref","first-page":"R137","DOI":"10.1186\/ar4318","article-title":"Tophus burden reduction with pegloticase: results from phase 3 randomized trials and open-label extension in patients with chronic gout refractory to conventional therapy","volume":"15","author":"Baraf","year":"2013","journal-title":"Arthritis Res Ther"},{"key":"R10-20230828","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.3899\/jrheum.080814","article-title":"Clinical efficacy and safety of successful long-term urate lowering with febuxostat or allopurinol in subjects with gout","volume":"36","author":"Becker","year":"2009","journal-title":"J Rheumatol"},{"key":"R11-20230828","first-page":"577","article-title":"Treatment of chronic gout. Can we determine when urate stores are depleted enough to prevent attacks of gout?","volume":"28","author":"Li-Yu","year":"2001","journal-title":"J Rheumatol"},{"key":"R12-20230828","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1056\/NEJMoa050373","article-title":"Febuxostat compared with allopurinol in patients with hyperuricemia and gout","volume":"353","author":"Becker","year":"2005","journal-title":"N Engl J Med"},{"key":"R13-20230828","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1002\/art.22232","article-title":"Using serum urate levels to determine the period free of gouty symptoms after withdrawal of long-term urate-lowering therapy: a prospective study","volume":"55","author":"Perez-Ruiz","year":"2006","journal-title":"Arthritis Care Res"},{"key":"R14-20230828","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1017\/S0317167100012981","article-title":"Serum urate and the risk of Parkinson's disease: results from a meta-analysis","volume":"40","author":"Shen","year":"2013","journal-title":"Can J Neurol Sci"},{"key":"R15-20230828","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1136\/annrheumdis-2012-201676","article-title":"Patients with gout adhere to curative treatment if informed appropriately: proof-of-concept observational study","volume":"72","author":"Rees","year":"2013","journal-title":"Ann Rhem Dis"},{"key":"R16-20230828","first-page":"2429","article-title":"Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis","volume":"31","author":"Borstad","year":"2004","journal-title":"J Rheumatol"},{"key":"R17-20230828","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1016\/j.clinthera.2011.01.008","article-title":"Effect of prophylaxis on gout flares after the initiation of urate-lowering therapy: analysis of data from three phase III trials","volume":"32","author":"Wortmann","year":"2010","journal-title":"Clin Ther"},{"key":"R18-20230828","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/nrrheum.2015.132","article-title":"Allopurinol hypersensitivity: investigating the cause and minimizing the risk","volume":"12","author":"Stamp","year":"2016","journal-title":"Nat Rev Rheum"},{"key":"R19-20230828","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1097\/ACI.0000000000000286","article-title":"Immunopathogenesis and risk factors for allopurinol severe cutaneous adverse reactions","volume":"16","author":"Wang","year":"2016","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"R20-20230828","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1007\/s40264-013-0084-0","article-title":"Allopurinol hypersensitivity: a systematic review of all published cases, 1995\u20132012","volume":"36","author":"Ramasamy","year":"2013","journal-title":"Drug Saf"},{"key":"R21-20230828","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1136\/annrheumdis-2014-205577","article-title":"Insights into the poor prognosis of allopurinol-induced severe cutaneous adverse reactions: the impact of renal insufficiency, high plasma levels of oxypurinol and granulysin","volume":"74","author":"Chung","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"R22-20230828","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0002-9343(84)90743-5","article-title":"Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency","volume":"76","author":"Hande","year":"1984","journal-title":"Am J Med"},{"key":"R23-20230828","first-page":"1646","article-title":"Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout","volume":"33","author":"Dalbeth","year":"2006","journal-title":"J Rheumatol"},{"key":"R24-20230828","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1002\/art.34488","article-title":"Starting dose, but not maximum maintenance dose, is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol","volume":"64","author":"Stamp","year":"2012","journal-title":"Arthritis Rheum"},{"key":"R25-20230828","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1002\/art.30119","article-title":"Using allopurinol above the dose based on creatinine clearance is effective and safe in chronic gout, including in those with renal impairment","volume":"63","author":"Stamp","year":"2011","journal-title":"Arthritis Rheum"},{"key":"R26-20230828","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1136\/ard.2008.091462","article-title":"A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300\u2013600\u200amg\/day versus benzbromarone 100\u2013200\u200amg\/day in patients with gout","volume":"68","author":"Reinders","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"R27-20230828","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1136\/ard.60.10.981","article-title":"Relationship between adverse events associated with allopurinol and renal function in patients with gout","volume":"60","author":"Vazquez-Mellado","year":"2001","journal-title":"Ann Rheum Dis"},{"key":"R28-20230828","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.semarthrit.2015.05.005","article-title":"An open-label, 6-month study of allopurinol safety in gout: The LASSO study","volume":"2015","author":"Becker","year":"2015","journal-title":"Semin Arthritis Rheum"},{"key":"R29-20230828","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1002\/art.39654","article-title":"Impact of febuxostat on renal function in gout subjects with moderate-to-severe renal impairment","volume":"68","author":"Saag","year":"2016","journal-title":"Arthritis Rheum"},{"key":"R30-20230828","doi-asserted-by":"crossref","first-page":"R63","DOI":"10.1186\/ar2978","article-title":"The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial","volume":"12","author":"Becker","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"R31-20230828","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.jbspin.2015.07.011","article-title":"Risk of cutaneous adverse events with febuxostat treatment in patients with skin reaction to allopurinol. A retrospective, hospital-based study of 101 patients with consecutive allopurinol and febuxostat treatment","volume":"83","author":"Bardin","year":"2016","journal-title":"Joint Bone Spine"},{"key":"R32-20230828","doi-asserted-by":"crossref","first-page":"659","DOI":"10.3899\/jrheum.111161","article-title":"Febuxostat hypersensitivity","volume":"39","author":"Abeles","year":"2012","journal-title":"J Rheumatol"},{"key":"R34-20230828","doi-asserted-by":"crossref","first-page":"872","DOI":"10.3899\/jrheum.121301","article-title":"Efficacy and tolerability of probenecid as urate-lowering therapy in gout; clinical experience in high-prevalence population","volume":"40","author":"Pui","year":"2013","journal-title":"J Rheumatol"},{"key":"R35-20230828","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1111\/imj.13173","article-title":"The safety and efficacy of benzbromarone in gout in Aotearoa New Zealand","volume":"46","author":"Stamp","year":"2016","journal-title":"Intern Med J"},{"key":"R36-20230828","doi-asserted-by":"crossref","first-page":"643","DOI":"10.2165\/00002018-200831080-00002","article-title":"A benefit-risk assessment of benzbromarone in the treatment of gout. Was its withdrawal from the market in the best interests of patients?","volume":"31","author":"Lee","year":"2008","journal-title":"Drug Safety"},{"key":"R37-20230828","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.amjmed.2011.09.033","article-title":"Comorbidities of gout and hyperuricemia in the US general population: NHANES 2007\u20132008","volume":"125","author":"Zhu","year":"2012","journal-title":"Am J Med"},{"key":"R38-20230828","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1097\/RHU.0000000000000091","article-title":"Challenges faced by patients in gout treatment: a qualitative study","volume":"20","author":"Singh","year":"2014","journal-title":"J Clin Rheumatol"},{"key":"R39-20230828","doi-asserted-by":"crossref","first-page":"975","DOI":"10.3899\/jrheum.141442","article-title":"Patient information about gout: an international review of existing educational resources","volume":"42","author":"Johnston","year":"2015","journal-title":"J Rheumatol"},{"key":"R40-20230828","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1002\/art.39813","article-title":"Effects of the Dietary approaches to Stop Hypertension (DASH) diet and sodium intake on serum uric acid","volume":"68","author":"Juraschek","year":"2016","journal-title":"Arthritis Rheum"},{"key":"R41-20230828","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1002\/art.21105","article-title":"The effects of vitamin C supplementation on serum concentrations of uric acid","volume":"52","author":"Huang","year":"2005","journal-title":"Arthritis Rheum"},{"key":"R42-20230828","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1002\/art.37925","article-title":"Clinically insignificant effect of supplemental vitamin C on serum urate in patients with gout; a pilot randomised controlled trial","volume":"65","author":"Stamp","year":"2013","journal-title":"Arthritis Rheum"},{"key":"R43-20230828","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/imj.12661","article-title":"Comprehensive dietary education in treated gout patients does not further improve serum urate","volume":"45","author":"Holland","year":"2015","journal-title":"Intern Med J"},{"key":"R44-20230828","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/RHU.0000000000000246","article-title":"An internet survey of common treatments used by patients with gout including cherry extract and juice and other dietary supplements","volume":"51","author":"Singh","year":"2015","journal-title":"Clin Rheumatol"},{"key":"R45-20230828","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1097\/RHU.0000000000000059","article-title":"Complementary and alternative medicine use in patients with gout","volume":"20","author":"Chan","year":"2013","journal-title":"J Clin Rheumatol"},{"key":"R46-20230828","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s13075-015-0624-3","article-title":"Comparative effectiveness of urate lowering with febuxostat versus allopurinol in gout: analyses from large U.S. managed care cohort","volume":"17","author":"Singh","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"R47-20230828","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1002\/acr.22336","article-title":"Medication adherence in gout: a systematic review","volume":"66","author":"De Vera","year":"2014","journal-title":"Arthritis Care Res"},{"key":"R48-20230828","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1186\/1471-2296-14-170","article-title":"Improvement in the management of gout is vital and overdue: an audit from a UK primary care medical practice","volume":"14","author":"Cottrell","year":"2013","journal-title":"BMC Fam Pract"},{"key":"R49-20230828","doi-asserted-by":"crossref","first-page":"e40","DOI":"10.2196\/jmir.3703","article-title":"Patient and provider attitudes toward the use of patient portals for the management of chronic disease: a systematic review","volume":"17","author":"Kruse","year":"2015","journal-title":"J Med Internet Res"},{"key":"R50-20230828","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.cct.2016.07.019","article-title":"Rationale and design of the randomized evaluation of an Ambulatory Care Pharmacist-Led Intervention to Optimize Urate Lowering Pathways (RAmP-UP) study","volume":"50","author":"Coburn","year":"2016","journal-title":"Contemp Clin Trials"},{"key":"R51-20230828","doi-asserted-by":"crossref","first-page":"e003627","DOI":"10.1136\/bmjopen-2013-003627","article-title":"Effectiveness of a pharmacist-based gout care management programme in a large integrated health plan: results from a pilot study","volume":"4","author":"Goldfien","year":"2014","journal-title":"BMJ Open"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00002281-201703000-00008","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T05:14:38Z","timestamp":1693199678000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00002281-201703000-00008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":50,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000000367","relation":{},"ISSN":["1040-8711","1531-6963"],"issn-type":[{"value":"1040-8711","type":"print"},{"value":"1531-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3]]}}}